论文部分内容阅读
目的平行对照分析重组人脑利钠肽联合硝普钠、米力农治疗难治性心力衰竭(RHF)的临床效果。方法将深圳市福田区第二人民医院2014年7月-2016年6月收治的120例RHF患者,随机分为观察组A(重-普组)60例,采用重组人脑利钠肽联合硝普钠治疗;观察组B(重-米组)60例,采用重组人脑利钠肽联合米力农治疗。比较两组患者治疗效果、并发症发生率。结果治疗后重-普组、重-米组患者LVEF值高于硝普纳组、米力农组,LVDD、LVWP、BNP、NE值低于硝普纳组、米力农组,差异有统计学意义(P<0.05);重-普组临床指标改善程度优于重-米组,差异有统计学意义(P<0.05)。重-普组、重-米组患者治疗有效率高于硝普纳组、米力农组,差异有统计学意义(P<0.05);重-普组治疗效果略优于重-米组,差异无统计学意义(P>0.05);且4组患者并发症发生率比较,差异无有统计学意义(P>0.05)。结论采用重组人脑利钠肽分别联合硝普钠、米力农治疗RHF,均能减轻患者心衰症状,改善心功能,控制病情发展。
Objective To compare the clinical effects of recombinant human brain natriuretic peptide combined with sodium nitroprusside and milrinone in the treatment of refractory heart failure (RHF). Methods A total of 120 RHF patients admitted to Futian Second People’s Hospital of Futian District from July 2014 to June 2016 were randomly divided into observation group A (n = 60) and recombinant human brain natriuretic peptide Pu sodium treatment; observation group B (weight - meter group) 60 cases, using recombinant human brain natriuretic peptide combined with milrinone treatment. The treatment effect and complication rate were compared between the two groups. Results After treatment, the values of LVEF were higher in the patients receiving weight-P group and weight-m group than those of the PT group, milrinone group, LVDD, LVWP and BNP, and the NE values were lower than those of the PT group and the milrinone group (P <0.05). The improvement of clinical indexes in the group of heavy-group was better than that of the group of heavy-group (P <0.05). The results showed that the treatment efficiency of the patients in the heavy-group and the heavy-group was higher than that in the nitrilotrid and milrinone groups (P <0.05) The difference was not statistically significant (P> 0.05). There was no significant difference in the complication rates between the four groups (P> 0.05). Conclusion Recombinant human brain natriuretic peptide combined with sodium nitroprusside and milrinone in the treatment of RHF can alleviate the symptoms of heart failure, improve cardiac function and control the progression of the disease.